Network meta-analysis of 18 RCTs (7281 adults with migraine and prior preventive failure): vs placebo, fremanezumab, eptinezumab, galcanezumab, atogepant and erenumab may most reduce monthly migraine days (MD −2.20 to −3.35); low-certainty evidence.
Meta-analysisn = 7,281
Khalili et al. Effectiveness and tolerability of pharmacological prophylaxis in migraine patients with prior preventive treatment failure: A systematic review and network meta-analysis of randomized controlled trials